# Treatment approaches for Gaucher disease
Gaucher disease is treated with various approaches, depending on the type of disease, the severity of symptoms, and how the condition progresses. The treatments aim to remove glucocerebroside, relieve symptoms, and prevent further damage.
Enzyme Replacement Therapy (ERT)
ProveniIncluded in official guidelines, or approved by EMA or FDA
In enzyme replacement therapy, the patient receives regular injections of an artificially made enzyme (imiglucerase or other variants). This enzyme replaces the enzyme that the body cannot make properly, and helps break down glucocerebroside. The enzyme works only in certain parts of the body; it does not reach the brain well.
The therapy is mainly used for type 1 and type 3 Gaucher disease. Studies from real-world settings, including in countries where this disease is more common, show that long-term treatment can reduce the size of the liver and spleen, decrease bone complaints, and improve blood cell counts. The effects become gradually visible over weeks to months.
Known side effects are reactions to the infusion itself (fever, chills, headache), which become less frequent as the body gets used to it. Some patients may develop antibodies against the enzyme, which can affect its effectiveness.
Substrate reduction therapy (SRT)
ProveniIncluded in official guidelines, or approved by EMA or FDA
This treatment works at a different level: instead of supplementing the broken-down enzyme, the production of glucocerebroside itself is inhibited. This means there is less 'waste' that the body cannot handle.
Different medicines in this group (miglustat, eliglustat, venglustat) are given orally or intravenously. They are used for type 1 and sometimes type 3 disease, and can be used both alone and as an addition to enzyme replacement.
The benefits appear similar to enzyme replacement: reduction of spleen and liver size, improved blood cells. Because these agents can reach areas that enzyme replacement cannot, there is interest in use for brain forms (type 2 and 3), but evidence is still limited.
Side effects vary by medicine, but can include diarrhea, tremor, concentration problems, and peripheral nerve disorders. Some medicines require regular monitoring of kidney function and other body functions.
Combination therapy
ProveniIncluded in official guidelines, or approved by EMA or FDA
Many patients receive enzyme replacement and substrate reduction at the same time. This may improve outcomes compared to one treatment alone, although this varies individually and always happens under the supervision of specialists.
Supportive treatments
ProveniIncluded in official guidelines, or approved by EMA or FDA
In addition to the specific anti-Gaucher therapies, patients also receive treatment for the consequences of the disease:
- **Bone strength**: bisphosphonates or other medicines to prevent osteoporosis, offered when bone demineralization is present.
- **Blood cells**: transfusions or medicines that stimulate the production of red and white blood cells if these are severely low.
- **Pain and movement**: physiotherapy, pain relief, and sometimes surgical interventions for severe bone complications.
- **Monitoring**: regular blood tests, imaging of organs, and specialist check-ups to detect complications early.
Gene therapy and experimental approaches
ResearchediPositive results in clinical studies, not yet standard treatment
Research with gene therapy (in which the defective gene is repaired with viral carriers) is ongoing at various stages. This addresses the problem at its source, but is not yet standard treatment. Recent research also explores new small-molecule substances (with names such as YH35995) that can penetrate the brain better, especially relevant for type 3 Gaucher disease.
Stem cell-like approach (induced pluripotent stem cells) is being investigated to better understand disease processes and possibly develop future therapies.
Treatment of neurological complications
ResearchediPositive results in clinical studies, not yet standard treatment
Because some forms of the disease also affect the nervous system, and because GBA gene mutations are linked to an increased risk of Parkinson-like symptoms, research is being conducted into medicines (such as rasagiline) to slow this neurological progression. This is not routine standard practice but part of ongoing studies.
Pregnancy and special circumstances
ProveniIncluded in official guidelines, or approved by EMA or FDA
For women with Gaucher disease who wish to become pregnant, guidelines exist. Enzyme replacement can continue; substrate reduction requires caution and individual assessment. This requires collaboration between a gynaecologist, metabolic specialist and patient.
---
_This information never replaces a doctor's judgment. Always discuss your situation with your own healthcare provider._